当前位置: X-MOL 学术Expert Opin. Biol. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy
Expert Opinion on Biological Therapy ( IF 4.6 ) Pub Date : 2021-06-28 , DOI: 10.1080/14712598.2021.1941862
M Galluzzo 1, 2 , G Caldarola 3, 4 , C De Simone 3, 4 , N Bernardini 5 , G Moretta 6 , S Pallotta 6 , E Botti 2, 7 , E Campione 2, 7 , F Pirro 3, 4 , C Potenza 5 , L Bianchi 2, 7 , K Peris 3, 4
Affiliation  

ABSTRACT

Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression.Results: After 48 weeks, 92.2% of patients (mean age 50.2 ± 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 ± 10.3 at baseline to 1.7 ± 3.9 and 1.4 ± 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks.

Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission.Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-to-severe chronic psoriasis in a real-world setting.



中文翻译:

使用 brodalumab 治疗慢性斑块状银屑病:在意大利拉齐奥地区进行的为期一年的真实生活研究

摘要

背景:评估brodalumab疗效和安全性的真实研究信息有限。研究设 在基线和 4、12、24、36 和 48 周后,通过银屑病面积和严重程度指数 (PASI) 评估疾病严重程度和治疗反应。通过逻辑回归评估 PASI 反应的预测因子。结果:48 周后,92.2% 的患者(平均年龄 50.2 ± 15 岁)接受 brodalumab 治疗的 PASI 评分 <3。PASI 评分从基线时的 17.4 ± 10.3 降至 12 周和 24 周时的 1.7 ± 3.9 和 1.4 ± 3.7,分别有 87.3%、81.8% 和 72.7% 的患者达到 PASI 75、90 和 100 48 周。

单变量回归显示,先前暴露于抗 IL17A 治疗与 36 至 48 周之间较差的 PASI 反应相关。在以前使用其他生物制剂失败的难以治疗的病例中,brodalumab 显着改善了结果,导致完全缓解。结论:在现实世界环境中,观察到 Brodalumab 对中度至重度慢性银屑病患者有效且安全。

更新日期:2021-06-28
down
wechat
bug